Evidence map›Paper›PMID 42369834›Full record

ReviewResearch (Washington, D.C.)2026

Foundation Models in Cancer Pathology: Techniques, Applications, and Future Directions.

Bo Zhang, Victor Yu Cui, Tong Wu, Guowei Su, Qinyi Huang, Bing Shang, Mei Kong, Weimiao Yu, Yuan Yuan, Huakang Tu

Abstract readReview
In one paragraph

Review in Research (Washington, D.C.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Bo ZhangCenter of Clinical Big Data and Analytics of the Second Affiliated Hospital and the School of Public Health, Zhejiang University School of Medicine, Hangzhou 310058, China.
Victor Yu CuiVanke School of Public Health, Tsinghua University, Beijing 100084, China.
Tong WuSchool of Public Health and Emergency Management, Southern University of Science and Technology, Shenzhen 518055, China.
Guowei SuCenter of Clinical Big Data and Analytics of the Second Affiliated Hospital and the School of Public Health, Zhejiang University School of Medicine, Hangzhou 310058, China.
Qinyi HuangCenter of Clinical Big Data and Analytics of the Second Affiliated Hospital and the School of Public Health, Zhejiang University School of Medicine, Hangzhou 310058, China.
Bing ShangCenter of Clinical Big Data and Analytics of the Second Affiliated Hospital and the School of Public Health, Zhejiang University School of Medicine, Hangzhou 310058, China.
Mei KongDepartment of Pathology, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou 310003, Zhejiang, China.
Weimiao YuIntelligent Digital and Molecular Pathology Lab, Bioinformatics Institute, A*STAR, Singapore 138671, Singapore.
Yuan YuanTumor Etiology and Screening Department of the Cancer Institute, and the Key Laboratory of Cancer Etiology and Prevention of Liaoning Education Department, the First Hospital of China Medical University, Shenyang 110001, China.
Huakang TuCenter of Clinical Big Data and Analytics of the Second Affiliated Hospital and the School of Public Health, Zhejiang University School of Medicine, Hangzhou 310058, China.ORCID https://orcid.org/0000-0002-8494-7327

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Computational pathology enables scalable analysis of pathology images for cancer diagnosis and research, but conventional deep learning models remain constrained by annotation dependence and task-specific development. Recent advances in self-supervised learning, transformer-based architectures, and large-scale pretraining have given rise to computational pathology foundation models (CPathFMs), which are designed to learn transferable and reusable representations from diverse pathology data. This review first traces the development of CPathFMs by examining the data resources, backbone architectures, representation levels, input modalities, and pretraining strategies that shape their design. We then examine their applications across major cancer pathology tasks, including tumor detection, grading, and subtyping, molecular biomarker and gene expression prediction, prognostic assessment, tissue phenotyping, as well as multimodal retrieval and report generation. We further discuss key challenges that limit translation and deployment, including underrepresentation of normal tissues and benign lesions, limited generalization across domains and institutions, data overlap and benchmark contamination, task-centric evaluation and insufficiently standardized metrics, high training and infrastructure costs, and ethical concerns in model governance. Overall, CPathFMs mark an important shift from task-specific pathology artificial intelligence toward reusable representation learning. Their clinical value remains to be established through improved model performance and generalizability, more comprehensive and standardized evaluation frameworks, and prospective evidence of utility in real-world pathology workflows.

Identifiers

PMID42369834
PMCPMC13305026

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.